Insider Purchases: Inside the Buy
Tag: featured-insiders
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.
🏥 Elevance Health (NYSE: ELV): The CEO Bought Again. We're Still Buying the Story.
Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.
💻 GitLab (GTLB): Triple CEO Buying, AI Tailwinds, a $400 Million Buyback, and Why This Software Leader May Be Too Cheap to Ignore
GitLab isn't simply riding the AI boom—it helps build it. With repeated insider buying by CEO William Staples, a $400 million buyback authorization, strong free cash flow, and an integrated DevSecOps platform, GitLab may represent one of enterprise software's more overlooked long-term opportunities.
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
💳 PayPal (PYPL): An 8× P/E, a CFO Insider Buy, and Why This FinTech Giant May Be Too Cheap to Ignore
PayPal has lost more than 85% of its value since 2021, yet it continues to grow revenue, generate billions in free cash flow, and aggressively repurchase shares. Has Wall Street become too pessimistic, or is PYPL a classic value trap? We examine the bull case, the risks, and what could reignite growth.
🏰 RH (NYSE: RH): Insider Buying, 34% Short Interest, and a Luxury Turnaround Worth Watching
RH isn't just selling luxury furniture anymore—it's trying to redefine luxury living. With a major insider purchase, elevated short interest, ambitious global expansion, and Wall Street split on the outlook, RH may be one of today's most intriguing turnaround stories.
📐 Autodesk (ADSK): Insider Buying, 58% Free Cash Flow Growth, and the AI "AIntegration" Opportunity
Autodesk isn't trying to beat AI—it may be one of the companies best positioned to integrate it. With executives buying shares, free cash flow soaring 58%, and a surprisingly attractive PEG ratio, ADSK deserves another look.
🎨 Adobe (ADBE) Stock Analysis: Why Eli Lilly CEO David Ricks Just Bought $1.9 Million of Adobe Stock
Wall Street says AI threatens Adobe. The numbers tell a different story. Revenue keeps hitting records, AI recurring revenue has tripled, valuation has collapsed to multi-year lows, and Eli Lilly CEO David Ricks just invested another $1.9 million of his own money. Here's why Adobe may deserve another look.
🩺 Abbott Laboratories (ABT) Stock Analysis: Can a Dividend King Turn Exact Sciences Into Its Next Growth Engine?
Abbott Laboratories may not be flashy, but the healthcare giant combines insider buying, a growing oncology diagnostics platform, the dominant FreeStyle Libre franchise, and more than a century of dividend payments. With shares trading near 16x forward earnings, investors may be looking at a classic Growth at a Reasonable Price opportunity.